Tokyo Tape
Sign in
← Falco Holdings

Quarterly report · Q2

4671.TEDINET S100PKQ2
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥24.2bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥50.0bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥24.7bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥1.7bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥3.1bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥1.9bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.3bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥1.9bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥3.3bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥1.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.1bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.1bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥2.1bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥38.7bnat 2022-09-30Cons.Assets
Total assets¥40.3bnat 2022-03-31Cons.Assets
Total assets¥39.1bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥14.4bnat 2022-09-30Cons.Liabilities
Total liabilities¥16.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥24.3bnat 2022-09-30Cons.Net assets
Net assets / equity¥23.5bnat 2022-03-31Cons.Net assets
Net assets / equity¥22.4bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥10.9bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥10.6bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥10.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.6bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥12.1bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥11.6bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥4.1bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥2.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥249m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥503m2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥937m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥2.4bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥107.52022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥65.162022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥3392021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥204.382021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥122.92021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥107.182022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥336.992021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥203.772021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio62.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio58.1%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio57.1%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥4m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥4m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥213m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥16.2bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥16.2bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥4m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.6bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥320m
—segment totalrevenue2022-04-01 → 2022-09-30¥24.2bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥24.2bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥4m
—segment totalsegment profit2022-04-01 → 2022-09-30¥2.0bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥8m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥177m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥16.6bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥16.6bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥7m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.8bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥8.1bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥8.1bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥523m
—segment totalrevenue2021-04-01 → 2021-09-30¥24.7bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥24.7bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥8m
—segment totalsegment profit2021-04-01 → 2021-09-30¥3.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 519
ItemContextValueUnit
Operating incomePrior1YTDDuration3136000000JPY
Operating incomeCurrentYTDDuration1741000000JPY
Dividends income noiPrior1YTDDuration61000000JPY
Dividends income noiCurrentYTDDuration73000000JPY
Reversal of allowance for doubtful accounts noiPrior1YTDDuration0JPY
Reversal of allowance for doubtful accounts noiCurrentYTDDuration0JPY
Subsidy income noiPrior1YTDDuration127000000JPY
Subsidy income noiCurrentYTDDuration35000000JPY
Other noiPrior1YTDDuration36000000JPY
Other noiCurrentYTDDuration43000000JPY
Non operating incomePrior1YTDDuration225000000JPY
Non operating incomeCurrentYTDDuration152000000JPY
Interest expenses noePrior1YTDDuration14000000JPY
Interest expenses noeCurrentYTDDuration10000000JPY
Commission fee noePrior1YTDDuration2000000JPY
Commission fee noeCurrentYTDDuration2000000JPY
Other noePrior1YTDDuration2000000JPY
Other noeCurrentYTDDuration3000000JPY
Non operating expensesPrior1YTDDuration19000000JPY
Non operating expensesCurrentYTDDuration16000000JPY
Ordinary incomePrior1YTDDuration3342000000JPY
Ordinary incomeCurrentYTDDuration1877000000JPY
Gain on sales of investment securities eiPrior1YTDDuration－JPY
Gain on sales of investment securities eiCurrentYTDDuration69000000JPY
Gain on transfer of business eiPrior1YTDDuration15000000JPY
Gain on transfer of business eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration15000000JPY
Extraordinary incomeCurrentYTDDuration69000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration0JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration3000000JPY
Loss on valuation of investment securities elPrior1YTDDuration－JPY
Loss on valuation of investment securities elCurrentYTDDuration18000000JPY
Impairment loss elPrior1YTDDuration11000000JPY
Impairment loss elCurrentYTDDuration0JPY
Extraordinary lossPrior1YTDDuration12000000JPY
Extraordinary lossCurrentYTDDuration22000000JPY
Income before income taxesPrior1YTDDuration3345000000JPY
Income before income taxesCurrentYTDDuration1924000000JPY
Income taxes currentPrior1YTDDuration1225000000JPY
Income taxes currentCurrentYTDDuration723000000JPY
Income taxes deferredPrior1YTDDuration-5000000JPY
Income taxes deferredCurrentYTDDuration74000000JPY
Income taxesPrior1YTDDuration1219000000JPY
Income taxesCurrentYTDDuration798000000JPY
Profit lossPrior1YTDDuration2125000000JPY
Profit lossCurrentYTDDuration1125000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration2125000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration1125000000JPY
Profit lossPrior1YTDDuration2125000000JPY
Profit lossCurrentYTDDuration1125000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass